Abstract
Gemcitabine (Gemzar) is a nucleoside analog increasingly used in the treatment of a variety of solid tumors. DNA synthesis is inhibited by gemcitabine by masked chain termination and via inhibition of ribonucleotide reductase. Synergy may exist between gemcitabine and other antimetabolites, including 5-fluorouracil. The varying patterns of dose-limiting toxicities to gemcitabine and UFT (uracil and tegafur in a 4:1 molar ratio) plus oral calcium folinate (Orzel) permit their use in combination. The primary aim of this phase I study is to determine the maximum tolerated doses of gemcitabine and UFT plus oral calcium folinate in patients with a variety of solid tumors. Only eight patients have been recruited to date, with myelosuppression being the main toxicity observed.
Publication types
-
Clinical Trial
-
Clinical Trial, Phase I
-
Comparative Study
-
Randomized Controlled Trial
MeSH terms
-
Aged
-
Aged, 80 and over
-
Antimetabolites, Antineoplastic / administration & dosage
-
Antimetabolites, Antineoplastic / therapeutic use*
-
Antineoplastic Combined Chemotherapy Protocols*
-
DNA, Neoplasm / drug effects
-
Deoxycytidine / administration & dosage
-
Deoxycytidine / analogs & derivatives*
-
Deoxycytidine / therapeutic use
-
Drug Administration Routes
-
Female
-
Follow-Up Studies
-
Gemcitabine
-
Humans
-
Leucovorin / administration & dosage
-
Leucovorin / therapeutic use*
-
Male
-
Middle Aged
-
Neoplasms / drug therapy*
-
Neoplasms / genetics
-
Ribonucleotide Reductases / antagonists & inhibitors
-
Tegafur / administration & dosage
-
Tegafur / therapeutic use
-
Treatment Outcome
-
Uracil / administration & dosage
-
Uracil / therapeutic use
Substances
-
Antimetabolites, Antineoplastic
-
DNA, Neoplasm
-
Deoxycytidine
-
Tegafur
-
Uracil
-
Ribonucleotide Reductases
-
Leucovorin
-
Gemcitabine